Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL399056 | 0.85 | LMNA (0.46) | LMNAALDH1A1MAPTPTGS2GLA | |
| SCHEMBL16972466 | 0.82 | ENPP2 (0.40) | LMNAALDH1A1MAPTPTGS2 | |
| SCHEMBL30540158 | 0.81 | LMNA (0.54) | LMNAALDH1A1MAPTPTGS2GLA | |
| SCHEMBL21491187 | 0.81 | LMNA (0.54) | LMNAALDH1A1MAPTPTGS2GLA | |
| SCHEMBL6901293 | 0.77 | ALDH1A1 (0.41) | ALDH1A1GAA | |
| SCHEMBL755309 | 0.76 | LMNA (0.60) | LMNAALDH1A1MAPTPTGS2GLA | |
| SCHEMBL15273624 | 0.76 | EPAS1 (0.39) | LMNAALDH1A1MAPTPTGS2 | |
| SCHEMBL1940207 | 0.76 | LMNA (0.38) | LMNAPTGS2 | |
| SCHEMBL3487760 | 0.75 | SMN1; SMN2 (0.59) | LMNAPTGS2 | |
| SCHEMBL28947225 | 0.75 | LMNA (0.44) | LMNAALDH1A1MAPTPTGS2GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470859-B2 | Iminopyridine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-25 | — | — | US | disclosed |
| EP-2535330-A2 | Iminopyridine derivative and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2012-12-19 | — | — | EP | disclosed |
| US-20100016315-A1 | Iminopyridine Derivative and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2077262-A1 | IMINOPYRIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016315-A1 | Iminopyridine Derivative and Use Thereof | ADRA1D, ADRB1, ADRB2 | LMNA 804/4885ALDH1A1 49/4885MAPT 2141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.